A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following CRS
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2020
Price : $35 *
At a glance
- Drugs Radspherin (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man
- Sponsors Oncoinvent
- 26 Jun 2019 Planned number of patients changed from 39 to 33.
- 26 Jun 2019 Planned End Date changed from 1 Jun 2022 to 1 Feb 2023.
- 26 Jun 2019 Planned initiation date changed from 1 Feb 2019 to 15 Dec 2019.